Comparative Biosciences, Inc. (CBI), a leading preclinical Contract Research Organization (CRO), has demonstrated expertise in all phases of the drug development process in preclinical contract dermatology studies. Due to CBI’s unique and extensive experience in dermatology studies and state-of-the-art facilities, we have the skill and expertise to accelerate new dermatology drugs, biologics, and devices from discovery through the drug development process, to regulatory submission and studies in man.
CBI is very pleased to announce that Dr. Howard Maibach, an international authority in dermatology, is now a Consultant and Scientific Advisor to CBI in the area of Dermatology. Dr. Maibach has written, lectured and published extensively on dermatotoxicology (the toxicity to man from skin exposure) and dermatopharmacology (the treatment of skin diseases). His current research programs include defining the chemical-biologic faces of irritant dermatitis and the study of percutaneous penetration.
Our highly specialized staff is experienced in providing exploratory/proof-of-concept, GLP toxicology, pharmacokinetics, in vivo animal models, pharmacology, and histopathology/immunohistochemistry in the area of dermatology for biotechnology, pharmaceutical, academic, defense, cosmetic, agricultural, and chemical organizations. CBI is versed in dermal studies employing small molecules, large molecules, biologics, chemicals, irritants, carcinogens, and dermal devices.
CBI conducts dermal studies in all species. Minipigs are a most important species for dermatologic assessments. Minipig skin is a close correlate to human skin in comparison to the skin morphology of rodents, guinea pigs and rabbits. CBI has over 10 years experience with minipigs in toxicology, dermatotoxicology, and dermal efficacy studies and recommends them as the nonrodent species of choice for dermatologic toxicology, pharmacokinetics and pharmacology.